scholarly journals Absence of Integrase Inhibitor-Associated Resistance Among Antiretroviral Therapy-Naïve HIV-1-Infected Adults in Guangdong Province, China, in 2018

2020 ◽  
Vol Volume 13 ◽  
pp. 4389-4394
Author(s):  
Yun Lan ◽  
Linghua Li ◽  
Weilie Chen ◽  
Xizi Deng ◽  
Junbin Li ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Guangdong Province ◽  
Integrase Inhibitor ◽  
Hiv 1

scholarly journals Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anna Prats ◽  
Ignacio Martínez-Zalacaín ◽  
Beatriz Mothe ◽  
Eugènia Negredo ◽  
Núria Pérez-Álvarez ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Integrase Inhibitor ◽  
Strand Transfer ◽  
Cognitive Differences ◽  
Integrase Strand Transfer Inhibitors ◽  
Initiation Of Therapy ◽  
Main Component ◽  
Living With Hiv ◽  
The Impact ◽  
Hiv 1

AbstractIntegrase strand transfer inhibitors (INSTI) are a main component of the current antiretroviral regimens recommended for treatment of HIV infection. However, little is known about the impact of INSTI on neurocognition and neuroimaging. We developed a prospective observational trial to evaluate the effects of INSTI-based antiretroviral therapy on comprehensive brain outcomes (cognitive, functional, and imaging) according to the time since HIV-1 acquisition. We recruited men living with HIV who initiated antiretroviral therapy with INSTI < 3 months since the estimated date of HIV-1 acquisition (n = 12) and > 6 months since estimated date of HIV-1 acquisition (n = 15). We also recruited a group of matched seronegative individuals (n = 15). Assessments were performed at baseline (before initiation of therapy in HIV arms) and at weeks 4 and 48. Baseline cognitive functioning was comparable between the arms. At week 48, we did not find cognitive differences between starting therapy with INSTI earlier than 3 months or later than 6 months after acquisition of HIV-1 infection. Functional status was poorer in individuals diagnosed earlier. This effect recovered 48 weeks after initiation of therapy. Regarding brain imaging, we found that men living with HIV initiating antiretroviral therapy later experienced a greater decrease in medial orbitofrontal cortex over time, with expected negative repercussions for decision-making tasks.

scholarly journals Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants

2019 ◽  
Vol 63 (5) ◽  
Author(s):  
Robert A. Smith ◽  
Dana N. Raugi ◽  
Vincent H. Wu ◽  
Christopher G. Zavala ◽  
Jennifer Song ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Antiviral Activity ◽  
Integrase Inhibitor ◽  
Single Cycle ◽  
Hiv 1

ABSTRACTWe compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.

scholarly journals In VitroAntiviral Activity of Cabotegravir against HIV-2

2018 ◽  
Vol 62 (10) ◽  
Author(s):  
Robert A. Smith ◽  
Vincent H. Wu ◽  
Christopher G. Zavala ◽  
Dana N. Raugi ◽  
Selly Ba ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Antiretroviral Therapy ◽  
Antiviral Activity ◽  
Integrase Inhibitor ◽  
Single Cycle ◽  
Preexposure Prophylaxis ◽  
Hiv 1 ◽  
Potential Option

ABSTRACTWe examined the antiviral activity of the integrase inhibitor (INI) cabotegravir against HIV-2 isolates from INI-naive individuals. HIV-2 was sensitive to cabotegravir in single-cycle and spreading-infection assays, with 50% effective concentrations (EC50s) in the low to subnanomolar range; comparable results were obtained for HIV-1 in both assay formats. Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings.

Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Suzan Dijkstra ◽  
L. Marije Hofstra ◽  
Tania Mudrikova ◽  
Annemarie M.J. Wensing ◽  
Patrick G.A. Oomen ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Lower Incidence ◽  
Integrase Inhibitor ◽  
Combination Antiretroviral Therapy ◽  
Hiv 1

scholarly journals Psychiatric Disorders after Switching to Dolutegravir: A Case Report of a 59-Year-Old Virosuppressed HIV-1 Positive Woman

2020 ◽  
Vol 2020 ◽  
pp. 1-2
Author(s):  
Daniele Mengato ◽  
Raffaella Binazzi ◽  
Ivan Unterholzner ◽  
Elke M. Erne ◽  
Alicia Tavella
Keyword(s):  
Case Report ◽  
Antiretroviral Therapy ◽  
Psychiatric Disorders ◽  
Psychiatric Symptoms ◽  
Beta Blockers ◽  
Integrase Inhibitor ◽  
Cardiovascular Disorders ◽  
Positive Woman ◽  
Tenofovir Alafenamide ◽  
Hiv 1

We report a case of a woman who experienced psychiatric disorders after switching her antiretroviral therapy (c-ART) to dolutegravir (DTG). She is a 59-year-old HIV-1 positive woman with a recent story of cardiovascular disorders treated with beta-blockers, clopidogrel, and rosuvastatin. She underwent a c-ART switch from darunavir/cobicistat and maraviroc to emtricitabine/tenofovir alafenamide fumarate in association with dolutegravir due to drug-drug interactions. One week later, she started to show psychiatric symptoms that required admission to the psychiatric unit. These disorders resolved within a couple of days after DTG discontinuation to allow a regular discharge. With this case-report, we would like to analyse the possible correlation between integrase inhibitor and severe psychiatric disorders in order to confirm the evidences already published in literature.

scholarly journals Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy

PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139474 ◽  
Author(s):  
Marie R. McCausland ◽  
Steven M. Juchnowski ◽  
David A. Zidar ◽  
Daniel R. Kuritzkes ◽  
Adriana Andrade ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Integrase Inhibitor ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document